Navigation Links
Global Sepsis Therapeutics Industry
Date:9/8/2011

NEW YORK, Sept. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Sepsis Therapeutics Industry

http://www.reportlinker.com/p0611042/Global-Sepsis-Therapeutics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_

This report analyzes the worldwide markets for Sepsis Therapeutics in US$ Million. Analytics refer to sales of drugs used in the direct treatment of severe sepsis/septic shock. The report provides separate comprehensive analytics for the US, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 33 companies including many key and niche players such as Agennix AG, AstraZeneca Plc, Artisan Pharma, Atox Bio, Inc., CytoGenix, Inc., Chong Kun Dang Pharmaceutical Corporation, Daiichi-Sankyo Company, Ltd., Endacea, Inc., Eli Lilly and Company, Medinox, Inc., and NexBio, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

2. INDUSTRY OVERVIEW 4

A Prelude 4

Snapshots 4

Table 1: Annual Incidence of Sepsis in the US and EU-27 5

Sepsis Treatment: An Untapped Market 5

Challenges Facing Sepsis Treatment 5

Lack of Awareness 5

Efforts to Enhance Awareness 6

Delayed Start of Treatment 6

Diagnostic Tools For Faster Treatment 7

Sepsis in Neonates: A Major Challenge 7

3. SEPSIS - AN INTRODUCTION 8

Sepsis - A Leading Killer 8

Risk Profile 8

Most Vulnerable Group: New Born and Elderly 8

A Growing Threat in Hospital Environment 9

Types of Sepsis 9

SIRS 9

Uncomplicated Sepsis 10

Severe Sepsis 10

Septic Shock 10

Septicemia 10

Bacteremia 10

Mortality Rates 11

Table 2: 28-Day Mortality Rate: Progression from Infection to

Septic Shock 11

Symptoms to Identify Sepsis Patients 11

General Symptoms in Sepsis Patients 11

Symptoms Specific to Source of Infection 12

Biological Changes in Sepsis Patients 12

Organ Dysfunction Symptoms in Acute Cases 12

Common Sources of Sepsis 13

Table 3: Primary Site of Infection Affected by Sepsis

(includes corresponding Graph/Chart) 13

Stages of Sepsis' Progression 13

Treatment of Sepsis 14

General Approaches for Treatment of Severe Sepsis and Septic

Shock 14

First Line of Treatment 15

Identifying Infection Source 15

Overview of Traditional Treatment Approaches 15

Corticosteroids 16

Immunoglobulins 16

Anticoagulants 17

Neonatal Sepsis 17

4. DRUGS FOR SEPSIS TREATMENT: AN OVERVIEW 18

Xigris - The Only Approved Treatment for Sepsis 18

Declining Sales: A Cause of Concern for Xigris Brand 18

PROWESS Study 19

Artisan Pharma's ART 123 19

AstraZeneca's CytoFab™ 19

Agennix's Talactoferrin 20

Chong Kun Dang Pharmaceutical's CKD-712 20

Eisai's Eritoran 20

Takeda's TAK-242 20

Current Development Status of Select Sepsis Drugs 21

Primary Completion Dates of Select Sepsis Therapeutics 22

5. STRATEGIC CORPORATE DEVELOPMENTS 23

Eisai's Eritoran Fails Phase III Trial 23

Rhode Island Hospital Identifies New Protein 23

Agennix Offers Data from Talactoferrin Phase II Trial 23

Nycomed Acquires Majority Interest in Guangdong Techpool Bio-

Pharma 23

Tianjin Chase Collaborates with Chongging Southwest Hospital

for Developing Sepsis Drug 24

Artisan Pharma Announces Phase IIb Study of ART-123 24

AstraZeneca Commences Phase IIb Trials for CytoFab™ 25

Medinox Collaborates with Orient Europharma for NOX-100 25

GPC Biotech Signs Business Combination Agreement with Agennix 25

Fast-Track Drugs & Biologics and Atox Bio Enter into

Collaboration 26

Sirius Genomics Enters into Agreement with Assistance

Publique-Hopitaux de Paris 26

Takeda Discontinues Compound Development for Severe Sepsis 27

BTG Acquires Protherics 27

Galapagos and UCL Sign Agreement 27

Artisan Pharma Receives Approval for ART-123 in Japan 27

6. FOCUS ON SELECT PLAYERS 28

Agennix AG (Germany) 28

AstraZeneca Plc (UK) 28

Artisan Pharma (US) 29

Atox Bio, Inc. (US) 29

CytoGenix, Inc. (US) 30

Chong Kun Dang Pharmaceutical Corporation (Korea) 30

Daiichi-Sankyo Company, Ltd. (Japan) 30

Endacea, Inc. (US) 31

Eli Lilly and Company (US) 31

Medinox, Inc. 32

NexBio, Inc. (US) 32

7. GLOBAL MARKET PERSPECTIVE 33

Table 4: World Recent Past, Current and Future Analysis for

Sepsis Drugs by Geographic Region - US and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) 33

Table 5: World Historic Review for Sepsis Drugs by Geographic

Region - US and Rest of World Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2003

through 2008 (includes corresponding Graph/Chart) 34

Table 6: World 15-Year Perspective for Sepsis Drugs by

Geographic Region - Percentage Breakdown of Value Sales for US

and Rest of World Markets for Years 2003, 2010, and 2017

(includes corresponding Graph/Chart) 34

8. THE UNITED STATES 35

A.Market Analysis 35

Outlook 35

Snapshots 35

Rising Incidence of Healthcare Infections 35

Sepsis: A Leading Cause of Mortality in the US 36

Table 7: Incidence and Mortality Rate of Select Diseases in

the US 36

Table 8: Number of Deaths Per Annum of Select Diseases in

the US 36

An Economic Burden 36

Risk of Sepsis in Neonates 37

Reimbursement Scenario 37

B.Market Analytics 38

Table 9: US Recent Past, Current and Future Analysis for

Sepsis Drugs Analyzed with Annual Sales Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) 38

Table 10: US Historic Review for Sepsis Drugs Analyzed with

Annual Sales Figures in US$ Million for Years 2003 through

2008 (includes corresponding Graph/Chart) 38

9. REST OF WORLD 39

A.Market Analysis 39

Outlook 39

Canada 39

Table 11: Mortality Rate (%) of Select Conditions in Canada 39

Europe 39

United Kingdom 39

Drotrecogin Alfa (Activated): Recommended for High-Risk

Sepsis Patients 40

The Netherlands 40

Poland 40

B.Market Analytics 41

Table 12: Rest of World Recent Past, Current and Future

Analysis for Sepsis Drugs Analyzed with Annual Sales Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) 41

Table 13: Rest of World Historic Review for Sepsis Drugs

Analyzed with Annual Sales Figures in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) 41

COMPETITIVE LANDSCAPE

Total Companies Profiled: 33 (including Divisions/Subsidiaries - 35)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 17

Canada 1

Japan 2

Europe 9

France 1

Germany 2

The United Kingdom 3

Rest of Europe 3

Asia-Pacific (Excluding Japan) 4

Middle East 2

------------------------------------------

To order this report:

Drug and Medication Industry: Global Sepsis Therapeutics Industry

Drug and Medication Business News

More  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endo Pharmaceuticals to Present at the UBS Global Life Sciences Conference
2. Amylin Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Cyberonics to Participate in 2011 UBS Global Life Sciences Conference
4. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
5. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
6. ReportsnReports - PV Ribbon Industry (China &Global), Fetal & Neonatal Care Equipment Market, WiMAX Market (TDD/FDD Spectrum)
7. Coronado Biosciences to Present at the Rodman & Renshaw Annual Global Investment Conference
8. Johnson & Johnson to Participate in Morgan Stanley Global Health Care Conference
9. JMIR Article by IHLS Authors Discusses Global Public Health Implications of Social Media Direct-to-Consumer Advertising by Illicit Online Pharmacies and Private Entities
10. MarketsandMarkets: Global Fetal and Neonatal Care Equipment Market Forecast (2011-2016)
11. SuperNova Diagnostics® to Present at the Rodman & Renshaw Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
Breaking Medicine News(10 mins):